OBJECTIVE: To evaluate whether transfusion of cell saver salvaged, stored at the bedside for up to 24 hrs, would decrease the number of postoperative allogeneic RBC transfusions and donor exposures, and possibly improve clinical outcomes. DESIGN: Prospective, randomized, controlled, clinical trial. SETTING:Pediatric cardiac intensive care unit. PATIENTS: Infants weighing less than 20 kg (n = 106) presenting for cardiac surgery with cardiopulmonary bypass. INTERVENTIONS: Subjects were randomized to a cell saver transfusion group where cell saver blood was available for transfusion up to 24 hrs after collection, or to a control group. Cell saver subjects received cell saver blood for volume replacement and/or RBC transfusions. Control subjects received crystalloid or albumin for volume replacement and RBCs for anemia. Blood product transfusions, donor exposures, and clinical outcomes were compared between groups. MEASUREMENTS AND MAIN RESULTS: Children randomized to the cell saver group had significantly fewer RBC transfusions (cell saver: 0.19 ± 0.44 vs. control: 0.75 ± 1.2; p = 0.003) and coagulant product transfusions in the first 48 hrs post-op (cell saver: 0.09 ± 0.45 vs. control: 0.62 ± 1.4; p = 0.013), and significantly fewer donor exposures (cell saver: 0.60 ± 1.4 vs. control: 2.3 ± 4.8; p = 0.019). This difference persisted over the first week post-op, but did not reach statistical significance (cell saver: 0.64 ± 1.24 vs. control: 1.1 ± 1.4; p = 0.07). There were no significant clinical outcome differences. CONCLUSION: Cell saver blood can be safely stored at the bedside for immediate transfusion for 24 hrs after collection. Administration of cell saver blood significantly reduces the number of RBC and coagulant product transfusions and donor exposures in the immediate postoperative period. Reduction of blood product transfusions has the potential to reduce transfusion-associated complications and decrease postoperative morbidity. Larger studies are needed to determine whether this transfusion strategy will improve clinical outcomes.
RCT Entities:
OBJECTIVE: To evaluate whether transfusion of cell saver salvaged, stored at the bedside for up to 24 hrs, would decrease the number of postoperative allogeneic RBC transfusions and donor exposures, and possibly improve clinical outcomes. DESIGN: Prospective, randomized, controlled, clinical trial. SETTING: Pediatric cardiac intensive care unit. PATIENTS: Infants weighing less than 20 kg (n = 106) presenting for cardiac surgery with cardiopulmonary bypass. INTERVENTIONS: Subjects were randomized to a cell saver transfusion group where cell saver blood was available for transfusion up to 24 hrs after collection, or to a control group. Cell saver subjects received cell saver blood for volume replacement and/or RBC transfusions. Control subjects received crystalloid or albumin for volume replacement and RBCs for anemia. Blood product transfusions, donor exposures, and clinical outcomes were compared between groups. MEASUREMENTS AND MAIN RESULTS:Children randomized to the cell saver group had significantly fewer RBC transfusions (cell saver: 0.19 ± 0.44 vs. control: 0.75 ± 1.2; p = 0.003) and coagulant product transfusions in the first 48 hrs post-op (cell saver: 0.09 ± 0.45 vs. control: 0.62 ± 1.4; p = 0.013), and significantly fewer donor exposures (cell saver: 0.60 ± 1.4 vs. control: 2.3 ± 4.8; p = 0.019). This difference persisted over the first week post-op, but did not reach statistical significance (cell saver: 0.64 ± 1.24 vs. control: 1.1 ± 1.4; p = 0.07). There were no significant clinical outcome differences. CONCLUSION: Cell saver blood can be safely stored at the bedside for immediate transfusion for 24 hrs after collection. Administration of cell saver blood significantly reduces the number of RBC and coagulant product transfusions and donor exposures in the immediate postoperative period. Reduction of blood product transfusions has the potential to reduce transfusion-associated complications and decrease postoperative morbidity. Larger studies are needed to determine whether this transfusion strategy will improve clinical outcomes.
Authors: Alaina K Kipps; David Wypij; Ravi R Thiagarajan; Emile A Bacha; Jane W Newburger Journal: Pediatr Crit Care Med Date: 2011-01 Impact factor: 3.624
Authors: Milo C Engoren; Robert H Habib; Anoar Zacharias; Thomas A Schwann; Christopher J Riordan; Samuel J Durham Journal: Ann Thorac Surg Date: 2002-10 Impact factor: 4.330
Authors: Joshua W Salvin; Mark A Scheurer; Peter C Laussen; David Wypij; Angelo Polito; Emile A Bacha; Frank A Pigula; Francis X McGowan; John M Costello; Ravi R Thiagarajan Journal: Ann Thorac Surg Date: 2011-01 Impact factor: 4.330
Authors: M J Dalrymple-Hay; S Dawkins; L Pack; C D Deakin; S Sheppard; S K Ohri; M P Haw; S A Livesey; J L Monro Journal: Cardiovasc Surg Date: 2001-04
Authors: Kathy J Jenkins; Kimberlee Gauvreau; Jane W Newburger; Thomas L Spray; James H Moller; Lisa I Iezzoni Journal: J Thorac Cardiovasc Surg Date: 2002-01 Impact factor: 5.209
Authors: Gavin J Murphy; Simon M Allen; Jonathon Unsworth-White; C Terence Lewis; Malcolm J R Dalrymple-Hay Journal: Ann Thorac Surg Date: 2004-05 Impact factor: 4.330
Authors: G W Laub; M Dharan; J B Riebman; C Chen; R Moore; B M Bailey; J Fernandez; M S Adkins; W Anderson; L B McGrath Journal: Chest Date: 1993-09 Impact factor: 9.410
Authors: Gilles A Orliaguet; Marie Bruyere; Philippe G Meyer; Stéphane Blanot; Dominique Renier; Pierre A Carli Journal: Paediatr Anaesth Date: 2003-11 Impact factor: 2.556
Authors: Ashley B Hodge; Thomas J Preston; Jill A Fitch; Sheilah K Harrison; Diane K Hersey; Kathleen K Nicol; Aymen N Naguib; Patrick I McConnell; Mark Galantowicz Journal: J Extra Corpor Technol Date: 2014-03
Authors: Laura Boulos; Joseph D Kuebler; Ron Angona; Dawn Sweeney; Hongyue Wang; Elizabeth Nocera; Jill M Cholette Journal: J Extra Corpor Technol Date: 2021-09
Authors: Joseph G Timpa; L Carlisle O'Meara; Kellen G Goldberg; Jay P Phillips; Jack H Crawford; Kimberly W Jackson; Jeffrey A Alten Journal: J Extra Corpor Technol Date: 2016-03
Authors: Allan Doctor; Jill M Cholette; Kenneth E Remy; Andrew Argent; Jeffrey L Carson; Stacey L Valentine; Scot T Bateman; Jacques Lacroix Journal: Pediatr Crit Care Med Date: 2018-09 Impact factor: 3.624
Authors: Jill M Cholette; Ariane Willems; Stacey L Valentine; Scot T Bateman; Steven M Schwartz Journal: Pediatr Crit Care Med Date: 2018-09 Impact factor: 3.624
Authors: Stacey L Valentine; Melania M Bembea; Jennifer A Muszynski; Jill M Cholette; Allan Doctor; Phillip C Spinella; Marie E Steiner; Marisa Tucci; Nabil E Hassan; Robert I Parker; Jacques Lacroix; Andrew Argent; Jeffrey L Carson; Kenneth E Remy; Pierre Demaret; Guillaume Emeriaud; Martin C J Kneyber; Nina Guzzetta; Mark W Hall; Duncan Macrae; Oliver Karam; Robert T Russell; Paul A Stricker; Adam M Vogel; Robert C Tasker; Alexis F Turgeon; Steven M Schwartz; Ariane Willems; Cassandra D Josephson; Naomi L C Luban; Leslie E Lehmann; Simon J Stanworth; Nicole D Zantek; Timothy E Bunchman; Ira M Cheifetz; James D Fortenberry; Meghan Delaney; Leo van de Watering; Karen A Robinson; Sara Malone; Katherine M Steffen; Scot T Bateman Journal: Pediatr Crit Care Med Date: 2018-09 Impact factor: 3.624